Hsing-Chen Tsai

Hsing-Chen Tsai

Auto-generated profile, based on publicly available information

Hsing-Chen Tsai

Graduate Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Molecular Cell
Verified
Journal Article
Closed access
HEHariharan Easwaran
Hariharan Easwaran
HTHsing-Chen Tsai
Hsing-Chen Tsai
SBStephen B. Baylin
Stephen B. Baylin

1 March 2012 in Cancer Cell
Verified
Journal Article
Closed access
HTHsing-Chen Tsai
Hsing-Chen Tsai
HLHuili Li
Huili Li
LNLeander Van Neste
Leander Van Neste
YCYi Cai
Yi Cai
CRCarine Robert
Carine Robert
CZCynthia Zahnow
Cynthia Zahnow

15 February 2011 in Cell Research
Verified
Journal Article
Closed access
HTHsing-Chen Tsai
Hsing-Chen Tsai
SBStephen B. Baylin
Stephen B. Baylin

30 September 2008 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JYJoo Mi Yi
Joo Mi Yi
HTHsing-Chen Tsai
Hsing-Chen Tsai
SGSabine C. GlöcKner
Sabine C. GlöcKner
SLSteven Lin
Steven Lin
JOJoyce E. Ohm
Joyce E. Ohm
SBStephen B. Baylin
Stephen B. Baylin
Much recent effort has focused on identifying and characterizing cellular markers that distinguish tumor propagating cells (TPC) from more differentiated progeny. We report here an unusual promoter DNA methylation pattern for one such marker, the cell surface antigen CD133 (Prominin 1). This protein has been extensively used to enrich putative cancer propagating stem-like cell populations in epithelial tumors and, especially, glioblastomas. We find that, within individual cell lines of cultured colon cancers and glioblastomas, the promoter CpG island of CD133 is DNA methylated, primarily, in cells with absent or low expression of the marker protein, whereas lack of such methylation is evident in purely CD133+ cells. Differential histone modification marks of active versus repressed genes accompany these DNA methylation changes. This heterogeneous CpG island DNA methylation status in the tumors is unusual in that other DNA hypermethylated genes tested in such cultures preserve their methylation patterns between separated CD133+ and CD133− cell populations. Furthermore, the CD133 DNA methylation seems to constitute an abnormal promoter signature because it is not found in normal brain and colon but only in cultured and primary tumors. Thus, the DNA methylation is imposed on the transition between the active versus repressed transcription state for CD133 only in tumors. Our findings provide additional insight for the dynamics of aberrant DNA methylation associated with aberrant gene silencing in human tumors. [Cancer Res 2008;68(19):8094–103]

23 February 2017 in Genome Research
Verified
Journal Article
Open access
PDF file
YCYi Cai
Yi Cai
HTHsing-Chen Tsai
Hsing-Chen Tsai
RYRay-Whay Chiu Yen
Ray-Whay Chiu Yen
YZYang W. Zhang
Yang W. Zhang
XKXiangqian Kong
Xiangqian Kong
SBStephen B. Baylin
Stephen B. Baylin
Reversing DNA methylation abnormalities and associated gene silencing, through inhibiting DNA methyltransferases (DNMTs) is an important potential cancer therapy paradigm. Maximizing this potential requires defining precisely how these enzymes maintain genome-wide, cancer-specific DNA methylation. To date, there is incomplete understanding of precisely how the three DNMTs, 1, 3A, and 3B, interact for maintaining DNA methylation abnormalities in cancer. By combining genetic and shRNA depletion strategies, we define not only a dominant role for DNA methyltransferase 1 (DNMT1) but also distinct roles of 3A and 3B in genome-wide DNA methylation maintenance. Lowering DNMT1 below a threshold level is required for maximal loss of DNA methylation at all genomic regions, including gene body and enhancer regions, and for maximally reversing abnormal promoter DNA hypermethylation and associated gene silencing to reexpress key genes. It is difficult to reach this threshold with patient-tolerable doses of current DNMT inhibitors (DNMTIs). We show that new approaches, like decreasing the DNMT targeting protein, UHRF1, can augment the DNA demethylation capacities of existing DNA methylation inhibitors for fully realizing their therapeutic potential.

1 November 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
WHWan-Chen Hsieh
Wan-Chen Hsieh
ELEn-Yu Lai
En-Yu Lai
YLYu-Ting Liu
Yu-Ting Liu
YWYi-Fu Wang
Yi-Fu Wang
YTYi-Shiuan Tzeng
Yi-Shiuan Tzeng
SCShih-Yu Chen
Shih-Yu Chen
To explore how the immune system controls clearance of SARS-CoV-2, we used a single-cell, mass cytometry–based proteomics platform to profile the immune systems of 21 patients who had recovered from SARS-CoV-2 infection without need for admission to an intensive care unit or for mechanical ventilation. We focused on receptors involved in interactions between immune cells and virus-infected cells. We found that the diversity of receptor repertoires on natural killer (NK) cells was negatively correlated with the viral clearance rate. In addition, NK subsets expressing the receptor DNAM1 were increased in patients who more rapidly recovered from infection. Ex vivo functional studies revealed that NK subpopulations with high DNAM1 expression had cytolytic activities in response to target cell stimulation. We also found that SARS-CoV-2 infection induced the expression of CD155 and nectin-4, ligands of DNAM1 and its paired coinhibitory receptor TIGIT, which counterbalanced the cytolytic activities of NK cells. Collectively, our results link the cytolytic immune responses of NK cells to the clearance of SARS-CoV-2 and show that the DNAM1 pathway modulates host-pathogen interactions during SARS-CoV-2 infection.